首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1984885

全球標靶癌症治療市場：按疾病、治療方法、最終用戶和地區分析—市場規模、行業趨勢、機會分析和未來預測（2026-2035 年）

Global Targeted Cancer Therapy Market: Analysis by Disease Indication, Therapy Type, End-User, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035

出版日期: 2026年02月01日 | 出版商:

Astute Analytica | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

標靶癌症治療市場需求強勁，成長顯著，預計2025年市場規模將達908.9億美元。據預測，未來十年該市場規模將成長近一倍，到2035年將達到驚人的1,754.8億美元。這一成長意味著2026年至2035年預測期內的複合年成長率將達到6.80%，反映了標靶癌症治療在全球範圍內的快速發展和日益普及。

多種因素推動了這一上升趨勢，但其中最重要的是精準腫瘤學的進步。精準腫瘤學透過實現針對個別腫瘤獨特分子和基因特徵的個人化治療，徹底改變了癌症治療。這種個人化治療提高了療效並最大限度地減少了副作用，使標靶治療對臨床醫生和患者都更具吸引力。抗體藥物複合體（ADC）的創新也發揮了至關重要的作用。 ADC結合了單株抗體的標靶化能力和強效細胞毒性藥物，能夠將殺死癌細胞的藥物直接且高度選擇性地遞送至癌細胞。

顯著的市場趨勢

標靶癌症治療市場的競爭格局由大型製藥企業主導，這些公司正積極透過策略性收購和投資來鞏固自身地位。Astra Zeneca憑藉其大獲成功的Enhertu系列產品，在抗體藥物複合體（ADC）領域佔主導地位。該產品組合使Astra Zeneca處於創新標靶治療的前沿，該公司已在該領域獲得顯著的市場佔有率，並正引領市場成長。

諾華是另一家在放射性藥物領域取得顯著進展的主要企業。其積極的擴張步伐體現在近期的收購中，例如以29億美元收購Morphosys以及以17.5億美元收購Mariana Oncology。這些投資凸顯了諾華致力於推動放射性藥物技術發展並拓展其靶向癌症療法產品線的決心，從而鞏固了其在該新興領域的領先地位。

2024年，百時美施貴寶（BMS）斥資41億美元收購RayzBio，此舉備受矚目。此次收購鞏固了BMS在錒系治療方法領域的戰略地位。錒系療法是一種極具前景的標靶癌症治療領域，它利用放射性同位素將強效治療作用直接傳遞至癌細胞。此交易不僅拓展了BMS的治療能力，也增強了其在腫瘤市場的競爭優勢。

主要成長要素

標靶癌症治療市場正經歷顯著成長，這主要得益於全球癌症發生率的上升。由於人口老化、生活方式改變和環境因素的影響，癌症發生率持續攀升，對創新有效治療方法的需求比以往任何時候都更加迫切。患者和醫療專業人員越來越傾向於尋求能夠提高存活率並改善生活品質的治療方法，同時盡可能減少傳統癌症治療中常見的嚴重副作用。

新機會的趨勢

標靶癌症治療是腫瘤學領域一項突破性的變革。它標誌著治療方式從傳統化療的廣泛且特異性方法，轉向一種被稱為精準醫療的更精準和個人化的治療模式。傳統化療透過不加選擇地攻擊體內快速增殖的細胞來發揮作用，但不幸的是，這不僅包括癌細胞，還包括毛囊、消化道和骨髓中的健康細胞。這種缺乏特異性會導致廣泛的全身性毒性以及許多副作用，例如脫髮、噁心和免疫功能減弱，從而可能嚴重影響患者的生活品質。

最佳化障礙

標靶治療的高成本是其廣泛應用的主要障礙，尤其是在中低收入國家，這可能會阻礙整體市場成長。部分標靶治療方法的費用高達每次療程90萬美元以上，反映了其研發、生產和治療的複雜性。如此高昂的價格使得許多醫療預算有限、健保覆蓋不足或缺失的患者難以負擔這些創新治療方法。這項經濟挑戰限制了這些國家醫療系統大規模推廣標靶治療的能力，阻礙了患者獲得能夠顯著改善治療效果的前沿癌症療法。

產業價值鏈分析
- 標靶識別和生物標記發現
- 生物製藥製造商
- 契約製造和CRO服務
- 分銷和專業藥房網路
- 醫院及癌症治療中心
產業展望
- 精準腫瘤學應用趨勢
- 研發管線趨勢與臨床試驗活動
- 監理和藥品核准趨勢
- 定價和兌換環境
- 生技藥品生產和供應鏈的發展趨勢
PESTLE分析
波特五力分析
- 供應商的議價能力
- 買方的議價能力
- 替代品的威脅
- 新進入者的威脅
- 競爭強度
市場成長及前景
- 市場獲利估算與預測（2020-2035）
- 依治療方法進行價格趨勢分析
市場吸引力分析
可執行的見解（分析師建議）

第4章：競爭對手儀錶板

市場集中度
企業市場占有率分析（2025 年）
競爭格局分析與基準測試
- 主要企業- 依地區

第5章：全球標靶癌症治療市場分析

市場動態和趨勢
- 成長要素
- 抑制因子
- 機會
- 主要趨勢
市場機會概述
透過治療方法
- 關鍵見解
- 市場規模及預測（2020-2035）
疾病特異性
- 關鍵見解
- 市場規模及預測（2020-2035）
最終用戶
- 關鍵見解
- 市場規模及預測（2020-2035）
依地區
- 關鍵見解
- 市場規模及預測（2020-2035）

第6章：北美標靶癌症治療市場分析

第7章：歐洲標靶癌症治療市場分析

第8章：亞太地區標靶癌症治療市場分析

第9章：中東和非洲標靶癌症治療市場分析

第10章：南美洲標靶癌症治療市場分析

第11章：公司簡介

Agenus, Inc.
Amgen, Inc.
Arcus Biosciences, Inc.
AstraZeneca Plc.
Aurinia Pharmaceuticals Inc.
Celdara Medical LLC
F. Hoffmann-La Roche &Co.
Genentech, Inc.
Gilead Sciences, Inc.
Nektar Therapeutics Inc.
Pfizer, Inc.
Serena Therapeutics Inc.
其他主要企業

第12章附錄

簡介目錄

Product Code: AA02261698

The targeted cancer therapy market is experiencing robust demand and significant growth, with its value estimated at USD 90.89 billion in 2025. Projections indicate that this market will nearly double over the next decade, reaching an impressive valuation of USD 175.48 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 6.80% during the forecast period from 2026 to 2035, reflecting the dynamic evolution and increasing adoption of targeted cancer treatments worldwide.

Several factors are fueling this upward trajectory, chief among them being advancements in precision oncology. Precision oncology has revolutionized cancer treatment by enabling therapies tailored to the unique molecular and genetic profiles of individual tumors. This personalization increases treatment efficacy while minimizing adverse effects, making targeted therapies more attractive to both clinicians and patients. Innovations in antibody-drug conjugates (ADCs) also play a pivotal role. ADCs combine the targeting capabilities of monoclonal antibodies with potent cytotoxic agents, allowing for highly selective delivery of cancer-killing drugs directly to tumor cells.

Noteworthy Market Developments

The competitive landscape of the targeted cancer therapy market is dominated by major pharmaceutical corporations that are actively strengthening their positions through strategic acquisitions and investments. AstraZeneca stands out as a dominant force, especially in the antibody-drug conjugate (ADC) segment, with its highly successful Enhertu franchise. This portfolio has positioned AstraZeneca at the forefront of innovative targeted therapies, enabling the company to capture significant market share and drive growth in this specialized area.

Novartis is another key player making substantial strides in the radiopharmaceutical sector. The company's aggressive expansion is highlighted by its recent acquisitions, including a USD 2.9 billion purchase of MorphoSys and a USD 1.75 billion acquisition of Mariana Oncology. These investments underscore Novartis's commitment to advancing radiopharmaceutical technologies and expanding its pipeline of targeted cancer treatments, reinforcing its leadership in this emerging field.

Bristol Myers Squibb (BMS) made a high-profile move in 2024 by acquiring RayzeBio for USD 4.1 billion. This acquisition secured BMS a strategic foothold in actinium-based therapies, a promising area of targeted cancer treatment that utilizes radioactive isotopes to deliver potent therapeutic effects directly to cancer cells. This deal not only expands BMS's therapeutic capabilities but also strengthens its competitive edge in the oncology market.

Core Growth Drivers

The market for targeted cancer therapies is experiencing significant growth driven primarily by the increasing incidence of cancer worldwide. As cancer rates continue to rise due to factors such as aging populations, lifestyle changes, and environmental influences, the demand for innovative and effective treatment options has become more urgent than ever. Patients and healthcare providers alike are seeking therapies that can not only improve survival rates but also enhance quality of life by minimizing the debilitating side effects often associated with traditional cancer treatments.

Emerging Opportunity Trends

Targeted cancer therapy marks a significant and transformative shift in the field of oncology, moving away from the broad, non-specific approach traditionally embodied by chemotherapy toward a more precise and individualized form of treatment known as precision medicine. Conventional chemotherapy operates by attacking rapidly dividing cells throughout the body without discrimination, which unfortunately includes not only cancer cells but also healthy cells found in hair follicles, the gastrointestinal tract, and bone marrow. This lack of specificity leads to widespread systemic toxicity, resulting in numerous side effects such as hair loss, nausea, and compromised immune function, which can severely impact a patient's quality of life.

Barriers to Optimization

The high cost of targeted therapies presents a significant barrier to widespread access, particularly in low-to middle-income countries, which could potentially impede overall market growth. Some of these therapies are priced at over $900,000 per treatment, reflecting the complexity of their development, manufacturing, and administration. Such steep price points place these innovative treatments out of reach for many patients in regions where healthcare budgets are limited, and insurance coverage is often insufficient or nonexistent. This economic challenge restricts the ability of healthcare systems in these countries to adopt targeted therapies on a large scale, limiting patient access to cutting-edge cancer treatments that could significantly improve outcomes.

Detailed Market Segmentation

Based on therapy, monoclonal antibodies are poised to capture a commanding position in the targeted cancer therapy market, expected to generate over 43% of the total revenue share. This strong financial dominance is rooted in their remarkable biological versatility, which allows these agents to serve multiple therapeutic functions. Initially developed as direct inhibitors targeting specific cancer cell markers, monoclonal antibodies have evolved to play critical roles as immune checkpoint inhibitors, effectively enhancing the body's immune response against tumors. Additionally, they are increasingly utilized as delivery vehicles for cytotoxic payloads, enabling the precise targeting and destruction of cancer cells while minimizing damage to healthy tissues.

Based on disease indication, Lung cancer has emerged as the leading disease indication within the targeted cancer therapy market, commanding more than 32% of the total market share. This dominance directly reflects the significant global burden posed by lung cancer, which remains the foremost cause of cancer-related mortality worldwide. Accounting for approximately 18.7% of all cancer deaths, lung cancer's impact is profound and far-reaching, underscoring the urgent need for effective treatment options.

Based on end user, hospitals represent the largest end-user segment in the targeted cancer therapy market, accounting for 58% of the total market share. This dominant position is largely due to the critical infrastructure hospitals provide for managing high-value biologics, many of which require specialized infusion protocols that can only be safely and effectively administered in a clinical setting. For instance, supportive care biologics such as Infliximab are predominantly delivered within hospital environments. This particular biologic is significant not only for its therapeutic role but also because it contributes to 32% of the overall biosimilar revenue, highlighting the financial and clinical importance of hospital-based administration.

Segment Breakdown

By Disease Indication

Colorectal Cancer
Breast Cancer
Gastrointestinal
Lung Cancer
Others

By Therapy Type

Signal Transduction Inhibitors
Monoclonal Antibodies
Small Molecule Inhibitors
Hormone Therapies
Others

By End-User

Cancer and Radiation Therapy Centers
Hospitals
Clinics

By Region

North America
Europe
Asia Pacific
Middle East and Africa
South America

Geography Breakdown

North America holds a commanding 39% share of the targeted cancer therapy market, a leadership position largely driven by the highly supportive regulatory environment in the United States. In 2024 alone, the U.S. Food and Drug Administration (FDA) approved 15 oncology drugs, signaling a robust pipeline of innovative treatments and creating an attractive landscape for investment and rapid commercialization. This proactive regulatory approach has been instrumental in fostering confidence among pharmaceutical companies and investors, encouraging them to accelerate their development and market entry efforts.
Capitalizing on this favorable environment, major industry players have made significant strategic moves to strengthen their foothold in the market. For example, Bristol Myers Squibb invested USD 4.1 billion to acquire RayzeBio, a move aimed at securing crucial radiopharmaceutical assets within the United States. This acquisition not only enhances Bristol Myers Squibb's portfolio but also underscores the importance of owning key therapeutic technologies domestically, aligning with broader industry trends prioritizing innovation and market access in North America.

Leading Market Participants

Agenus, Inc.
Amgen, Inc.
Arcus Biosciences, Inc.
AstraZeneca Plc.
Aurinia Pharmaceuticals Inc.
Celdara Medical LLC
F. Hoffmann-La Roche & Co.
Genentech, Inc.
Gilead Sciences, Inc.
Nektar Therapeutics Inc.
Pfizer, Inc.
Serena Therapeutics Inc.
Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Targeted Cancer Therapy Market

Chapter 2. Report Description

2.1. Research Framework
- 2.1.1. Research Objective
- 2.1.2. Market Definitions
- 2.1.3. Market Segmentation
2.2. Research Methodology
- 2.2.1. Market Size Estimation
- 2.2.2. Qualitative Research
  - 2.2.2.1. Primary & Secondary Sources
- 2.2.3. Quantitative Research
  - 2.2.3.1. Primary & Secondary Sources
- 2.2.4. Breakdown of Primary Research Respondents, By Region
- 2.2.5. Data Triangulation
- 2.2.6. Assumption for Study

Chapter 3. Global Targeted Cancer Therapy Market Overview

3.1. Industry Value Chain Analysis
- 3.1.1. Target Identification & Biomarker Discovery
- 3.1.2. Biopharmaceutical Manufacturers
- 3.1.3. Contract Manufacturing & CRO Services
- 3.1.4. Distribution & Specialty Pharmacy Networks
- 3.1.5. Hospitals & Oncology Treatment Centers
3.2. Industry Outlook
- 3.2.1. Precision Oncology Adoption Trends
- 3.2.2. Pipeline Landscape & Clinical Trial Activity
- 3.2.3. Regulatory & Drug Approval Trends
- 3.2.4. Pricing & Reimbursement Environment
- 3.2.5. Biologics Manufacturing & Supply Chain Trends
3.3. PESTLE Analysis
3.4. Porter's Five Forces Analysis
- 3.4.1. Bargaining Power of Suppliers
- 3.4.2. Bargaining Power of Buyers
- 3.4.3. Threat of Substitutes
- 3.4.4. Threat of New Entrants
- 3.4.5. Degree of Competition
3.5. Market Growth and Outlook
- 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
- 3.5.2. Price Trend Analysis, By Therapy Type
3.6. Market Attractiveness Analysis
3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

4.1. Market Concentration Rate
4.2. Company Market Share Analysis (Value %), 2025
4.3. Competitor Mapping & Benchmarking
- 4.3.1. Key players - By Region

Chapter 5. Global Targeted Cancer Therapy Market Analysis

5.1. Market Dynamics and Trends
- 5.1.1. Growth Drivers
- 5.1.2. Restraints
- 5.1.3. Opportunity
- 5.1.4. Key Trends
5.2. Market Opportunity Snapshot
5.3. By Therapy Type
- 5.3.1. Key Insights
- 5.3.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  - 5.3.2.1. Monoclonal Antibodies
  - 5.3.2.2. Small Molecule Inhibitors
  - 5.3.2.3. Signal Transduction Inhibitors
  - 5.3.2.4. Hormone Therapies
  - 5.3.2.5. Others
5.4. By Disease Indication
- 5.4.1. Key Insights
- 5.4.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  - 5.4.2.1. Lung Cancer
  - 5.4.2.2. Breast Cancer
  - 5.4.2.3. Colorectal Cancer
  - 5.4.2.4. Gastrointestinal Cancer
  - 5.4.2.5. Others
5.5. By End User
- 5.5.1. Key Insights
- 5.5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  - 5.5.2.1. Hospitals
  - 5.5.2.2. Cancer & Radiation Therapy Centers
  - 5.5.2.3. Clinics
5.6. By Region
- 5.6.1. Key Insights
- 5.6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  - 5.6.2.1. North America
    - 5.6.2.1.1. The U.S.
    - 5.6.2.1.2. Canada
    - 5.6.2.1.3. Mexico
  - 5.6.2.2. Europe
    - 5.6.2.2.1. Western Europe
      - 5.6.2.2.1.1. The UK
      - 5.6.2.2.1.2. Germany
      - 5.6.2.2.1.3. France
      - 5.6.2.2.1.4. Italy
      - 5.6.2.2.1.5. Spain
      - 5.6.2.2.1.6. Rest of Western Europe
    - 5.6.2.2.2. Eastern Europe
      - 5.6.2.2.2.1. Poland
      - 5.6.2.2.2.2. Russia
      - 5.6.2.2.2.3. Rest of Eastern Europe
  - 5.6.2.3. Asia Pacific
    - 5.6.2.3.1. China
    - 5.6.2.3.2. India
    - 5.6.2.3.3. Japan
    - 5.6.2.3.4. South Korea
    - 5.6.2.3.5. Australia & New Zealand
    - 5.6.2.3.6. ASEAN
    - 5.6.2.3.7. Rest of Asia Pacific
  - 5.6.2.4. Middle East & Africa
    - 5.6.2.4.1. UAE
    - 5.6.2.4.2. Saudi Arabia
    - 5.6.2.4.3. South Africa
    - 5.6.2.4.4. Rest of MEA
  - 5.6.2.5. South America
    - 5.6.2.5.1. Argentina
    - 5.6.2.5.2. Brazil
    - 5.6.2.5.3. Rest of South America

Chapter 6. North America Targeted Cancer Therapy Market Analysis

6.1. Market Dynamics and Trends
- 6.1.1. Growth Drivers
- 6.1.2. Restraints
- 6.1.3. Opportunity
- 6.1.4. Key Trends
6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 6.2.1. By Therapy Type
- 6.2.2. By Disease Indication
- 6.2.3. By End User
- 6.2.4. By Country

Chapter 7. Europe Targeted Cancer Therapy Market Analysis

7.1. Market Dynamics and Trends
- 7.1.1. Growth Drivers
- 7.1.2. Restraints
- 7.1.3. Opportunity
- 7.1.4. Key Trends
7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 7.2.1. By Therapy Type
- 7.2.2. By Disease Indication
- 7.2.3. By End User
- 7.2.4. By Country

Chapter 8. Asia Pacific Targeted Cancer Therapy Market Analysis

8.1. Market Dynamics and Trends
- 8.1.1. Growth Drivers
- 8.1.2. Restraints
- 8.1.3. Opportunity
- 8.1.4. Key Trends
8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 8.2.1. By Therapy Type
- 8.2.2. By Disease Indication
- 8.2.3. By End User
- 8.2.4. By Country

Chapter 9. Middle East & Africa Targeted Cancer Therapy Market Analysis

9.1. Market Dynamics and Trends
- 9.1.1. Growth Drivers
- 9.1.2. Restraints
- 9.1.3. Opportunity
- 9.1.4. Key Trends
9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 9.2.1. By Therapy Type
- 9.2.2. By Disease Indication
- 9.2.3. By End User
- 9.2.4. By Country

Chapter 10. South America Targeted Cancer Therapy Market Analysis

10.1. Market Dynamics and Trends
- 10.1.1. Growth Drivers
- 10.1.2. Restraints
- 10.1.3. Opportunity
- 10.1.4. Key Trends
10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 10.2.1. By Therapy Type
- 10.2.2. By Disease Indication
- 10.2.3. By End User
- 10.2.4. By Country